Charles Schwab Investment Management Inc. Acquires 78,969 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Charles Schwab Investment Management Inc. grew its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 4.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,983,240 shares of the biotechnology company’s stock after purchasing an additional 78,969 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Ironwood Pharmaceuticals were worth $8,786,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pacer Advisors Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 4.0% in the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after purchasing an additional 450,949 shares in the last quarter. State Street Corp boosted its stake in shares of Ironwood Pharmaceuticals by 7.3% in the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock valued at $40,870,000 after purchasing an additional 677,024 shares in the last quarter. FMR LLC boosted its stake in shares of Ironwood Pharmaceuticals by 25.1% in the 3rd quarter. FMR LLC now owns 169,681 shares of the biotechnology company’s stock valued at $699,000 after purchasing an additional 34,089 shares in the last quarter. Weiss Asset Management LP acquired a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at $893,000. Finally, Walleye Capital LLC boosted its stake in shares of Ironwood Pharmaceuticals by 264.2% in the 3rd quarter. Walleye Capital LLC now owns 280,299 shares of the biotechnology company’s stock valued at $1,155,000 after purchasing an additional 203,331 shares in the last quarter.

Ironwood Pharmaceuticals Stock Down 7.8 %

Shares of NASDAQ IRWD opened at $1.41 on Friday. The firm’s 50-day simple moving average is $2.27 and its 200 day simple moving average is $3.49. The company has a market cap of $225.64 million, a price-to-earnings ratio of -47.00 and a beta of 0.37. Ironwood Pharmaceuticals, Inc. has a 12-month low of $1.34 and a 12-month high of $9.01.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.08). The company had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. On average, equities analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 41,269 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now directly owns 554,007 shares in the company, valued at approximately $975,052.32. This represents a 6.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the transaction, the chief executive officer now owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 192,381 shares of company stock worth $338,591. Company insiders own 12.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Craig Hallum reduced their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Finally, JMP Securities reduced their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $8.60.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.